eng Science and Education Publishing Journal of Cancer Research and Treatment 2374-2003 2017-06-21 5 3 77 85 10.12691/jcrt-5-3-1 JCRT2017531 article Jaume Capdevila 1 Federico Rojo 2 Antonio González-Martín 3 Enrique Grande 4 Salvador Martín-Algarra 5 Javier Puente 6 Begoña Soler López bsoler@ecbio.net 7 Ruth Vera 7 Jesús García-Foncillas 8 Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain Pathology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain Anderson Cancer Center, Medical Oncology Department Madrid, Spain Hospital Universitario Ramón y Cajal, Medical Oncology Department, Madrid, Spain Medical Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain Medical Oncology Department, Hospital Clínico Universitario San Carlos, Thoracic, Urologic & Melanoma Cancer Unit, Madrid, Spain Medical Department, Las Rozas (Madrid), Spain Department of Oncology, University Hospital “Fundación Jiménez Díaz”, Autonomous University of Madrid, Madrid, Spain In the past five years, technological advances in the field of precision medicine in oncology have led to the emergence of a number of commercially available services for tumor profiling. There is an increased acceptance of these services that can help in finding treatment options based on molecular alterations as individual case reports have shown outstanding response to targeted therapies. Tumor profiling must seek to augment, rather than replace, existing local testing with the objective of helping more patients to find appropriate treatment options. The opportunity has arrived to integrate these services into the clinical setting, specifically in cases of refractory and rare tumors. The promise of precision medicine is clear but conclusive demonstration of how each of the different services delivers on the promise is not uniformly forthcoming. The selection of which service is most appropriate must be based on demonstrated analytical validation, quality standards, and data on clinical benefit and utility. The aims of this paper are to evaluate three tumor tissue profiling services commercially available and to propose to the physician how molecular profiling information can be used in clinical treatment decisions today. http://pubs.sciepub.com/jcrt/5/3/1/jcrt-5-3-1.pdf molecular profiling cancer precision medicine refractory tumors rare tumors